"Shire rose 62p to £10.60 after UBS said AstraZeneca could bid for the smaller drug group at a 40 per cent premium – £14.25 in cash – and still create value. It doubted that Pfizer would be interested."
http://business.timesonline.co.uk/tol/business/markets/article3579212.ece
Wednesday, March 19, 2008
SHP
